Intranasal oxytocin may improve odds of abstinence in cocaine-dependent patients: results from a preliminary study
Background: Oxytocin (OT) treatment in drug addiction studies have suggested potential therapeutic benefits. There is a paucity of clinical trial studies of oxytocin in cocaine use disorders. Method: This was a 6-week randomized, double-blind, outpatient clinical trial study investigating the effect...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-03-01
|
| Series: | Drug and Alcohol Dependence Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772724621000160 |
| _version_ | 1818358402676424704 |
|---|---|
| author | Wilfrid Noël Raby Matthew Heller Demetrios Milliaressis C. Jean Choi Cale Basaraba Martina Pavlicova Daniel M. Alschuler Frances R. Levin Sarah Church Edward V. Nunes |
| author_facet | Wilfrid Noël Raby Matthew Heller Demetrios Milliaressis C. Jean Choi Cale Basaraba Martina Pavlicova Daniel M. Alschuler Frances R. Levin Sarah Church Edward V. Nunes |
| author_sort | Wilfrid Noël Raby |
| collection | DOAJ |
| description | Background: Oxytocin (OT) treatment in drug addiction studies have suggested potential therapeutic benefits. There is a paucity of clinical trial studies of oxytocin in cocaine use disorders. Method: This was a 6-week randomized, double-blind, outpatient clinical trial study investigating the effect of daily Intranasal Oxytocin (24 IU) on cocaine use by cocaine use disorder patients. After a 7-day inpatient abstinence induction stage, patients were randomized to intranasal oxytocin or intranasal placebo. During the outpatient phase, cocaine use disorder patients were required to present themselves to the research staff 3 times a week for witnessed randomized medication administration, to provide a urine sample for qualitative toxicology, and complete mandatory assessments, including the Time-Line-Follow Back. For the interim days, patients were given an “at-home” bottle that was weighed at each clinic visit to monitor compliance. Results: Neither administration of Intranasal placebo (n = 11) or Oxytocin (n = 15) induced at least 3 weeks of continuous abstinence. However, from week 3, the odds of weekly abstinence increased from 4.61 (95% CI = 1.05, 20.3) to 15.0 (CI = 1.18, 190.2) by week 6 for the Intranasal Oxytocin group (t = 2.12, p = 0.037), though there was no significant group difference overall in the odds of abstinence over time (F1,69 = 1.73, p = 0.19). More patients on Intranasal Oxytocin dropped out (p = 0.0005). Conclusions: Intranasal Oxytocin increased the odds of weekly abstinence in Cocaine patients after 2 weeks compared to PBO, but was associated with a higher dropout rate. (ClinicalTrials.gov 02,255,357, 10/2014) |
| first_indexed | 2024-12-13T20:28:26Z |
| format | Article |
| id | doaj.art-461d1e1d235c4594aad5d7f5022fe38d |
| institution | Directory Open Access Journal |
| issn | 2772-7246 |
| language | English |
| last_indexed | 2024-12-13T20:28:26Z |
| publishDate | 2022-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Drug and Alcohol Dependence Reports |
| spelling | doaj.art-461d1e1d235c4594aad5d7f5022fe38d2022-12-21T23:32:29ZengElsevierDrug and Alcohol Dependence Reports2772-72462022-03-012100016Intranasal oxytocin may improve odds of abstinence in cocaine-dependent patients: results from a preliminary studyWilfrid Noël Raby0Matthew Heller1Demetrios Milliaressis2C. Jean Choi3Cale Basaraba4Martina Pavlicova5Daniel M. Alschuler6Frances R. Levin7Sarah Church8Edward V. Nunes9Division on Substance Abuse, Department of Psychiatry, Montefiore Medical Center, Albert Einstein College of Medicine, 1510 Waters Place, 2nd Floor, Bronx, NY 10461, United States of America; Division on Substance Use Disorders, Department of Psychiatry, Columbia University Irving Medical Center and the New York State Psychiatric Institute, New York, NY, United States of America; Corresponding author at: Division on Substance Abuse, Department of Psychiatry, Montefiore Medical Center, Albert Einstein College of Medicine, 1510 Waters Place, 2nd Floor, Bronx, NY 10461, United States of America.Division on Substance Use Disorders, Department of Psychiatry, Columbia University Irving Medical Center and the New York State Psychiatric Institute, New York, NY, United States of AmericaDivision on Substance Use Disorders, Department of Psychiatry, Columbia University Irving Medical Center and the New York State Psychiatric Institute, New York, NY, United States of AmericaDivision of Mental Health Data Science, New York State Psychiatric Institute, New York, NY, United States of AmericaDivision of Mental Health Data Science, New York State Psychiatric Institute, New York, NY, United States of AmericaDepartment of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY, United States of AmericaDivision of Mental Health Data Science, New York State Psychiatric Institute, New York, NY, United States of AmericaDivision on Substance Use Disorders, Department of Psychiatry, Columbia University Irving Medical Center and the New York State Psychiatric Institute, New York, NY, United States of AmericaWholeview Wellness Centers, 369 Lexington Avenue, Suite 14A, New York City, NY 10017, United States of AmericaDivision on Substance Use Disorders, Department of Psychiatry, Columbia University Irving Medical Center and the New York State Psychiatric Institute, New York, NY, United States of AmericaBackground: Oxytocin (OT) treatment in drug addiction studies have suggested potential therapeutic benefits. There is a paucity of clinical trial studies of oxytocin in cocaine use disorders. Method: This was a 6-week randomized, double-blind, outpatient clinical trial study investigating the effect of daily Intranasal Oxytocin (24 IU) on cocaine use by cocaine use disorder patients. After a 7-day inpatient abstinence induction stage, patients were randomized to intranasal oxytocin or intranasal placebo. During the outpatient phase, cocaine use disorder patients were required to present themselves to the research staff 3 times a week for witnessed randomized medication administration, to provide a urine sample for qualitative toxicology, and complete mandatory assessments, including the Time-Line-Follow Back. For the interim days, patients were given an “at-home” bottle that was weighed at each clinic visit to monitor compliance. Results: Neither administration of Intranasal placebo (n = 11) or Oxytocin (n = 15) induced at least 3 weeks of continuous abstinence. However, from week 3, the odds of weekly abstinence increased from 4.61 (95% CI = 1.05, 20.3) to 15.0 (CI = 1.18, 190.2) by week 6 for the Intranasal Oxytocin group (t = 2.12, p = 0.037), though there was no significant group difference overall in the odds of abstinence over time (F1,69 = 1.73, p = 0.19). More patients on Intranasal Oxytocin dropped out (p = 0.0005). Conclusions: Intranasal Oxytocin increased the odds of weekly abstinence in Cocaine patients after 2 weeks compared to PBO, but was associated with a higher dropout rate. (ClinicalTrials.gov 02,255,357, 10/2014)http://www.sciencedirect.com/science/article/pii/S2772724621000160IntranasalOxytocinCocaineStress |
| spellingShingle | Wilfrid Noël Raby Matthew Heller Demetrios Milliaressis C. Jean Choi Cale Basaraba Martina Pavlicova Daniel M. Alschuler Frances R. Levin Sarah Church Edward V. Nunes Intranasal oxytocin may improve odds of abstinence in cocaine-dependent patients: results from a preliminary study Drug and Alcohol Dependence Reports Intranasal Oxytocin Cocaine Stress |
| title | Intranasal oxytocin may improve odds of abstinence in cocaine-dependent patients: results from a preliminary study |
| title_full | Intranasal oxytocin may improve odds of abstinence in cocaine-dependent patients: results from a preliminary study |
| title_fullStr | Intranasal oxytocin may improve odds of abstinence in cocaine-dependent patients: results from a preliminary study |
| title_full_unstemmed | Intranasal oxytocin may improve odds of abstinence in cocaine-dependent patients: results from a preliminary study |
| title_short | Intranasal oxytocin may improve odds of abstinence in cocaine-dependent patients: results from a preliminary study |
| title_sort | intranasal oxytocin may improve odds of abstinence in cocaine dependent patients results from a preliminary study |
| topic | Intranasal Oxytocin Cocaine Stress |
| url | http://www.sciencedirect.com/science/article/pii/S2772724621000160 |
| work_keys_str_mv | AT wilfridnoelraby intranasaloxytocinmayimproveoddsofabstinenceincocainedependentpatientsresultsfromapreliminarystudy AT matthewheller intranasaloxytocinmayimproveoddsofabstinenceincocainedependentpatientsresultsfromapreliminarystudy AT demetriosmilliaressis intranasaloxytocinmayimproveoddsofabstinenceincocainedependentpatientsresultsfromapreliminarystudy AT cjeanchoi intranasaloxytocinmayimproveoddsofabstinenceincocainedependentpatientsresultsfromapreliminarystudy AT calebasaraba intranasaloxytocinmayimproveoddsofabstinenceincocainedependentpatientsresultsfromapreliminarystudy AT martinapavlicova intranasaloxytocinmayimproveoddsofabstinenceincocainedependentpatientsresultsfromapreliminarystudy AT danielmalschuler intranasaloxytocinmayimproveoddsofabstinenceincocainedependentpatientsresultsfromapreliminarystudy AT francesrlevin intranasaloxytocinmayimproveoddsofabstinenceincocainedependentpatientsresultsfromapreliminarystudy AT sarahchurch intranasaloxytocinmayimproveoddsofabstinenceincocainedependentpatientsresultsfromapreliminarystudy AT edwardvnunes intranasaloxytocinmayimproveoddsofabstinenceincocainedependentpatientsresultsfromapreliminarystudy |